Medical Device Security Disclosure: MDS2 Explained, Vulnerability Reporting, and FDA Guidance

Overview of Medical Device Security Disclosure

Medical device security disclosure is the structured sharing of a device’s cybersecurity posture so you can evaluate risk before and after deployment. It connects procurement, implementation, and ongoing operations with clear, actionable details.

The Manufacturer Disclosure Statement for Medical Device Security (MDS2) is the industry-standard tool for this purpose. It helps align premarket security assessment with real-world deployment and supports postmarket surveillance once devices are in clinical use.

Effective disclosure also includes a public vulnerability disclosure policy, defined response timelines, and communication paths with customers. Together, these practices reduce uncertainty and improve patient safety.

Components of the MDS2 Form

The MDS2 form summarizes how a device protects data, resists attacks, and can be safely maintained. While formats vary by revision, you will typically see the following components addressed in clear, testable terms.

Device identification and environment

• Model, software/firmware versions, supported operating systems, and connectivity types.
• Clinical use cases and whether standalone, networked, or cloud-connected operation is required.

Data protection and encryption

• Protection of data at rest and in transit, including cryptographic algorithms and key management.
• Support for secure time synchronization and integrity checks to prevent tampering.

Device access control and authentication mechanisms

• User provisioning, roles, and least-privilege enforcement, including role-based access control.
• Local and remote authentication mechanisms (password policies, certificates, tokens, MFA, or biometrics where applicable).

Audit logging and monitoring

• Events captured (logins, configuration changes, clinical actions) and retention periods.
• Export formats and integration with security monitoring tools for incident investigations.

Network security and hardening

• Open ports/services, segmentation recommendations, and secure remote service options.
• Wireless security capabilities and protections against unauthorized connections.

Software patch management and update strategy

• How patches are delivered, authenticated, and installed with safety in mind.
• Expected update cadence, support windows, and rollback/backup procedures.

Supply chain transparency

• Third-party components and whether a software bill of materials (SBOM) is provided.
• Policies for tracking vulnerable components and deprecating risky dependencies.

Physical security and servicing

• Protections against unauthorized physical access and secure maintenance workflows.
• Safeguards for removable media and controlled use of service accounts.

Safety considerations and residual risk

• Security controls evaluated against clinical safety risks and documented residual risks.
• Known limitations and compensating controls that customers should implement.

Vulnerability Reporting Processes

A predictable, well-documented process turns ad hoc vulnerability reports into timely, safe fixes. It should be codified in a coordinated vulnerability disclosure policy and aligned with your quality system.

1) Intake and acknowledgement

• Publish a clear reporting channel and security.txt or equivalent contact details.
• Acknowledge receipt quickly, provide a tracking ID, and outline next steps and timelines.

2) Triage and risk assessment

• Validate reproducibility, affected versions, and clinical configurations.
• Score severity and patient safety impact; prioritize by exploitability and prevalence.

3) Containment and compensating controls

• Share interim mitigations with customers when patches are not immediately available.
• Coordinate with partners and service teams to reduce exposure across fleets.

4) Remediation and verification

• Develop and test patches using formal change control and regression testing.
• Verify fixes in representative clinical environments to avoid workflow disruption.

5) Disclosure and deployment

• Issue customer notifications with clear instructions, risk summaries, and update prerequisites.
• Provide version identifiers, reboot/clinical downtime expectations, and rollback guidance.

6) Postmarket surveillance and improvement

• Monitor field feedback, update advisories as needed, and measure deployment progress.
• Conduct a post-incident review to strengthen processes and reduce future time-to-fix.

FDA Guidance on Medical Device Security

FDA expectations emphasize cybersecurity risk management across the device life cycle. You should demonstrate secure-by-design engineering in premarket submissions and maintain robust postmarket practices.

Premarket expectations

• Threat modeling tied to clinical hazards and design controls that mitigate misuse scenarios.
• Documented cybersecurity architecture, device access control, and authentication mechanisms.
• Plans for software patch management, vulnerability intake, and update capabilities for the device’s supported life.
• Supply chain governance, including SBOMs and processes to handle third‑party vulnerabilities.

Postmarket practices

• Ongoing monitoring, rapid risk evaluation, and timely remediation to protect patients and networks.
• Clear communication to customers about risk, mitigations, and validated updates.
• Use of field data to refine controls and feed improvements back into design.

Importance of Timely Security Disclosures

Timely disclosure narrows the attacker window, helps clinicians make informed decisions, and reduces operational surprises. It also builds trust with customers and regulators by showing accountable stewardship.

Transparent, scheduled updates limit unplanned downtime and prevent risky workarounds. Rapidly sharing mitigations empowers healthcare delivery organizations to implement compensating controls while awaiting patches.

Over time, predictable disclosures lower total cost of ownership by speeding risk acceptance, procurement, and safe deployment.

Risk Management Using MDS2

MDS2 is most powerful when you operationalize it. Treat it as a living artifact that maps device capabilities to your clinical risk register and security policies.

Before procurement

• Use MDS2 to compare vendors on encryption, access control, logging, and update mechanisms.
• Identify gaps requiring network segmentation, enhanced monitoring, or contractual commitments.

During implementation

• Translate MDS2 claims into technical controls: firewall rules, identity integrations, and backup procedures.
• Validate settings in a test environment and document residual risks with owners and timelines.

In operations and postmarket surveillance

• Align maintenance windows with the vendor’s software patch management plan.
• Track vulnerabilities against the SBOM and verify that mitigations are applied across the fleet.

Implementing Security by Design in Medical Devices

Security by design means embedding protections into architecture, code, and maintenance from day one. It reduces costly rework and produces clearer, more credible MDS2 disclosures.

Architect for least privilege and resilience

• Enforce role separation, harden defaults, and isolate safety‑critical functions.
• Use signed updates, secure boot, and recovery images to withstand compromise.

Engineer a secure development life cycle

• Integrate threat modeling, static/dynamic analysis, and secure code reviews.
• Continuously assess third‑party components and retire vulnerable dependencies promptly.

Plan for updates and supportability

• Design authenticated, reliable update paths that respect clinical workflows.
• Publish a vulnerability disclosure policy with SLAs; measure and improve time‑to‑patch.

Operate with transparency

• Provide customers with deployment checklists, change logs, and rollback guidance.
• Report known limitations candidly so HDOs can layer compensating controls.

Key takeaways

• Use MDS2 to make security capabilities visible and comparable.
• Back disclosures with strong authentication mechanisms, device access control, and reliable patching.
• Align premarket security assessment with postmarket surveillance for a continuous risk management loop.

FAQs

What is the purpose of the MDS2 form?

MDS2 provides a standardized, vendor‑supplied summary of a device’s cybersecurity controls so you can assess risk, plan compensating measures, and maintain compliance. It turns marketing claims into concrete details you can verify and operationalize.

How should medical device vulnerabilities be reported?

Follow the manufacturer’s vulnerability disclosure policy to submit findings through a designated channel. Expect acknowledgement, triage, risk assessment, mitigations if needed, and a validated software update, plus clear customer guidance for safe deployment.

What are FDA’s recommendations for medical device cybersecurity?

FDA emphasizes life‑cycle cybersecurity risk management: secure architecture, strong access control and authentication, planned software patch management, vulnerability handling, SBOM transparency, and ongoing postmarket monitoring with timely remediation and communication.

How does security disclosure improve patient safety?

Clear, timely disclosure helps you reduce exposure, apply mitigations, and deploy patches without disrupting care. By aligning clinical workflows with transparent updates, it lowers the chance that a cybersecurity issue becomes a patient safety event.